TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07265570: A Phase IIa, Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of ISM5411 in Adult Patients With Active Ulcerative Coli

Sponsor: InSilico Medicine Hong Kong Limited · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$414,000

Rescue Site Savings

+$276,000

Unlock Full NCT07265570 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07265570 Rescue Dossier →